[Source: GenomeWeb News] – Intrinsic Bioprobes will measure cancer-related proteins and peptides that may improve diagnostic capabilities for disease, under a two-and-a-half year contract with the National Cancer Institute, the company said today.
Under the agreement, Intrinsic Bioprobes will receive $1.1 million from NCI, while the company will provide $146,000 toward the project.
The contract will support NCI’s Clinical Proteomic Technologies for Cancer initiative, which focuses on assessing and using proteomics technologies and data resources to solve critical problems in cancer research.
Intrinsic Bioprobes focuses on mass spectrometry-based assays and platforms for rapid biomarker analysis, and its technologies include the Mass Spectrometric Immunoassay and the Bioreactive Mass Spectrometer Probes. These technologies are used in the firm’s Massay System, which is a high-throughput mass spectrometry platform for rapid proteome analysis.
For more information click here.